CollPlant Biotechnologies Past Earnings Performance
Past criteria checks 0/6
CollPlant Biotechnologies's earnings have been declining at an average annual rate of -12.6%, while the Biotechs industry saw earnings growing at 15% annually. Revenues have been growing at an average rate of 5.8% per year.
Key information
-12.6%
Earnings growth rate
10.5%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 5.8% |
Return on equity | -24.8% |
Net Margin | -64.0% |
Next Earnings Update | 29 May 2024 |
Recent past performance updates
Recent updates
We're Interested To See How CollPlant Biotechnologies (NASDAQ:CLGN) Uses Its Cash Hoard To Grow
Feb 03Is CollPlant Biotechnologies (NASDAQ:CLGN) In A Good Position To Deliver On Growth Plans?
Nov 02CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) Shares Lagging The Industry But So Is The Business
Sep 06Here's Why We're Watching CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation
Jul 14Here's Why We're Not Too Worried About CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation
Mar 02Companies Like CollPlant Biotechnologies (NASDAQ:CLGN) Are In A Position To Invest In Growth
Nov 10CollPlant Non-GAAP EPS of -$0.36, revenue of $0.07M
Aug 25We Think CollPlant Biotechnologies (NASDAQ:CLGN) Can Afford To Drive Business Growth
Jul 22CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 22CollPlant Biotechnologies - A Cheap, Game-Changing Bio-Printing Platform Company
Aug 05Why We Think Shareholders May Be Considering Bumping Up CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) CEO Compensation
Jul 29The Strong Earnings Posted By CollPlant Biotechnologies (NASDAQ:CLGN) Are A Good Indication Of The Strength Of The Business
Jun 09Revenue & Expenses Breakdown
How CollPlant Biotechnologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 11 | -7 | 6 | 10 |
30 Sep 23 | 11 | -7 | 7 | 9 |
30 Jun 23 | 11 | -7 | 7 | 9 |
31 Mar 23 | 1 | -17 | 7 | 9 |
31 Dec 22 | 0 | -17 | 7 | 10 |
30 Sep 22 | 1 | -16 | 6 | 9 |
30 Jun 22 | 1 | -15 | 6 | 9 |
31 Mar 22 | 1 | -14 | 6 | 8 |
31 Dec 21 | 16 | 0 | 6 | 8 |
30 Sep 21 | 16 | 1 | 6 | 7 |
30 Jun 21 | 20 | 5 | 6 | 6 |
31 Mar 21 | 20 | 6 | 6 | 5 |
31 Dec 20 | 6 | -6 | 5 | 4 |
30 Sep 20 | 6 | -7 | 4 | 4 |
30 Jun 20 | 3 | -11 | 4 | 4 |
31 Mar 20 | 2 | -11 | 4 | 4 |
31 Dec 19 | 2 | -11 | 4 | 4 |
30 Sep 19 | 6 | -6 | 3 | 5 |
30 Jun 19 | 6 | -6 | 4 | 4 |
31 Mar 19 | 5 | -4 | 3 | 5 |
31 Dec 18 | 5 | -6 | 4 | 4 |
30 Sep 18 | 1 | -6 | 4 | 4 |
30 Jun 18 | 1 | -6 | 3 | 3 |
31 Mar 18 | 1 | -7 | 3 | 4 |
31 Dec 17 | 0 | -6 | 2 | 4 |
30 Sep 17 | 0 | -6 | 3 | 4 |
30 Jun 17 | 0 | -7 | 3 | 4 |
31 Mar 17 | 0 | -7 | 3 | 4 |
31 Dec 16 | 0 | -7 | 3 | 4 |
30 Sep 16 | 0 | -7 | 2 | 5 |
30 Jun 16 | 0 | -7 | 2 | 4 |
31 Mar 16 | 0 | -6 | 2 | 4 |
31 Dec 15 | 0 | -5 | 2 | 3 |
30 Sep 15 | 0 | -4 | 1 | 3 |
30 Jun 15 | 0 | -4 | 1 | 3 |
31 Mar 15 | 0 | -3 | 1 | 2 |
31 Dec 14 | 0 | -3 | 1 | 2 |
30 Sep 14 | 0 | -4 | 1 | 3 |
30 Jun 14 | 0 | -4 | 1 | 3 |
31 Mar 14 | 0 | -4 | 1 | 3 |
31 Dec 13 | 0 | -5 | 1 | 4 |
30 Sep 13 | 0 | -5 | 1 | 4 |
Quality Earnings: CLGN is currently unprofitable.
Growing Profit Margin: CLGN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CLGN is unprofitable, and losses have increased over the past 5 years at a rate of 12.6% per year.
Accelerating Growth: Unable to compare CLGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CLGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: CLGN has a negative Return on Equity (-24.77%), as it is currently unprofitable.